{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:54:36Z","timestamp":1792583676311,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2018,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Familial hypercholesterolemia (FH) and other extreme elevations in low-density lipoprotein cholesterol significantly increase the risk of atherosclerotic cardiovascular disease; however, recent data suggest that prescription rates for statins remain low in these patients. National rates of screening, awareness, and treatment with statins among individuals with FH or severe dyslipidemia are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from the 1999 to 2014 National Health and Nutrition Examination Survey were used to estimate prevalence rates of self-reported screening, awareness, and statin therapy among US adults (n=42\u2009471 weighted to represent 212 million US adults) with FH (defined using the Dutch Lipid Clinic criteria) and with severe dyslipidemia (defined as low-density lipoprotein cholesterol levels \u2265190 mg\/dL). Logistic regression was used to identify sociodemographic and clinical correlates of hypercholesterolemia awareness and statin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The estimated US prevalence of definite\/probable FH was 0.47% (standard error, 0.03%) and of severe dyslipidemia was 6.6% (standard error, 0.2%). The frequency of cholesterol screening and awareness was high (&gt;80%) among adults with definite\/probable FH or severe dyslipidemia; however, statin use was uniformly low (52.3% [standard error, 8.2%] of adults with definite\/probable FH and 37.6% [standard error, 1.2%] of adults with severe dyslipidemia). Only 30.3% of patients with definite\/probable FH on statins were taking a high-intensity statin. The prevalence of statin use in adults with severe dyslipidemia increased over time (from 29.4% to 47.7%) but not faster than trends in the general population (from 5.7% to 17.6%). Older age, health insurance status, having a usual source of care, diabetes mellitus, hypertension, and having a personal history of early atherosclerotic cardiovascular disease were associated with higher statin use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Despite the high prevalence of cholesterol screening and awareness, only \u224850% of adults with FH are on statin therapy, with even fewer prescribed a high-intensity statin; young and uninsured patients are at the highest risk for lack of screening and for undertreatment. This study highlights an imperative to improve the frequency of cholesterol screening and statin prescription rates to better identify and treat this high-risk population. Additional studies are needed to better understand how to close these gaps in screening and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.117.032321","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T05:30:17Z","timestamp":1522042217000},"page":"2218-2230","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":143,"title":["Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999\u20132014)"],"prefix":"10.1161","volume":"137","author":[{"given":"Emily M.","family":"Bucholz","sequence":"first","affiliation":[{"name":"Department of Medicine (E.M.B.)"},{"name":"Boston Children\u2019s Hospital, MA. Harvard Medical School, Boston, MA (E.M.B., S.D.d.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Mae","family":"Rodday","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA (A.M.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kolor","sequence":"additional","affiliation":[{"name":"Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA (K.K., M.J.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muin J.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA (K.K., M.J.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"de Ferranti","sequence":"additional","affiliation":[{"name":"Department of Cardiology (S.D.d.F.)"},{"name":"Boston Children\u2019s Hospital, MA. Harvard Medical School, Boston, MA (E.M.B., S.D.d.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.11.1413"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222403"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh236"},{"key":"e_1_3_4_5_2","volume-title":"In: Genereviews","author":"Youngblom E","year":"1993","unstructured":"Youngblom E, Pariani M, Knowles JW. Familial hypercholesterolemia. , Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K. In: Genereviews. Seattle, WA:University of Washington, Seattle; 1993."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.054"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2376"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2340"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.5162"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1563"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.05.007"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv289"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000297"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022335"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018791"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.006"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn422"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.8543"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2423"},{"key":"e_1_3_4_21_2","first-page":"1","article-title":"National Health and Nutrition Examination Survey: analytic guidelines, 1999\u20132010.","volume":"2","author":"Johnson CL","year":"2013","unstructured":"Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, Curtin LR. National Health and Nutrition Examination Survey: analytic guidelines, 1999\u20132010. Vital Health Stat. 2013:2;1\u201324.","journal-title":"Vital Health Stat"},{"key":"e_1_3_4_22_2","unstructured":"National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention. October 31 2017. https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm. Accessed December 18 2017."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.08.269"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.59700"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S005"},{"key":"e_1_3_4_27_2","volume-title":"Medicaid and CHIP eligibility levels","year":"2016","unstructured":"Medicaid and CHIP eligibility levels. Baltimore, MD: Centers for Medicare & Medicaid Services; 2016. https:\/\/www.medicaid.gov\/medicaid\/program-information\/medicaid-and-chip-eligibility-levels\/index.html. Accessed June 3, 2017."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001381"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.986349"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.03.001"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.01.002"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(98)00047-6"},{"key":"e_1_3_4_36_2","unstructured":"National Cholesterol Education Program. Detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Heart Lung and Blood Institute. NIH Publication No. 02-5215. September 2002. https:\/\/www.nhlbi.nih.gov\/files\/docs\/resources\/heart\/atp-3-cholesterol-full-report.pdf. Accessed June 28 2017."},{"key":"e_1_3_4_37_2","first-page":"S75","article-title":"American Diabetes Association. Cardiovascular disease and risk management. Sec. 9. In Standards of Medical Care in Diabetes-2017.","volume":"40","year":"2017","unstructured":"American Diabetes Association. Cardiovascular disease and risk management. Sec. 9. In Standards of Medical Care in Diabetes-2017. Diab Care. 2017;40(suppl 1):S75\u2013S87.","journal-title":"Diab Care"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01356.x"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.037"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2014.09.011"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.117.032321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:52:33Z","timestamp":1715572353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.117.032321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":39,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,5,22]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.117.032321"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.117.032321","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"2017-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}